The partnership pairs computational design with high-throughput experimental validation in a single, fast loop, the companies state. Most biologics that fail in development do not fail because they cannot bind their target. They fail on expression, stability, or other developability liabilities that surface only late, after years of sequential testing. By designing for those properties early and confirming them experimentally at scale, the collaboration resolves them where they are cheapest to fix, the companies state.

Rayca and Data Powered Therapeutics

Rayca contributes a discovery engine that models therapeutic targets in motion, designs candidate molecules with structure-aware generative methods, and screen them against binding thermodynamics using free-energy methods, all before a single molecule is made. Data Powered Therapeutics contributes a platform that automates wet-lab data generation at scale, expressing, purifying, and characterizing panels of up to a thousand nanobody variants in parallel and measuring binding, stability, solubility, specificity, and expression in a single automated run.

“The rate-limiting step in modern drug discovery is no longer compute but experimental evidence at scale. Our platform was built to generate it, characterising nanobody panels in parallel across binding, stability, and solubility, and compressing more than a year of sequential work into automated runs that return decision-grade data in weeks,” said Nikolay Dobrev, CEO of Data Powered Therapeutics. “Allied to Rayca’s modelling, that empirical foundation moves candidate quality upstream, resolving developability before it becomes a liability and focusing both teams on the molecules with the clearest path to the clinic.”

Addresses some of the most difficult settings in oncology

The program addresses some of the most difficult settings in oncology, including cancers that have grown resistant to standard therapy, tumors that evade the immune system, and aggressive neuroendocrine cancers such as small cell lung cancer, including disease that has spread to the brain. It spans several therapeutic mechanisms, including targeted protein degradation through a nanobody bioPROTAC approach, with further mechanisms advancing under the agreement, several of which carry first-in-class potential. Specific targets remain confidential at this stage.

“In therapeutic discovery, binding affinity is rarely the limiting step. Programmes fail downstream, on expression, stability, and the biophysical liabilities that decide whether a candidate can survive development. We built Rayca to confront that attrition at the design stage, treating developability as a primary and letting every programme build on the intelligence of the last,” says Pouya Behrouzi, CEO of Rayca Precision. “Pairing our modelling and collective intelligence with Data Powered Therapeutics’ high-throughput characterisation lets evidence sharpen every design, and brings differentiated nanobody therapeutics to cancers that resist current treatment.”

The companies intend to advance the lead programmes toward development candidates and to expand the portfolio over time.